HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

VCRP Modernization Snags Outlined By FDA As Program Resumes

This article was originally published in The Rose Sheet

Executive Summary

The Voluntary Cosmetics Registration Program modernization process could face a variety of potential roadblocks, FDA Division of Programs and Enforcement Policy Director Raymond Decker stated at the Cosmetic, Toiletry and Fragrance Association's "Meet the Regulators" conference in Bethesda, Md. Feb. 2.

You may also be interested in...



FDA Cosmetics & Colors Permanent Director Sought But Not Imminent

FDA Office of Cosmetics & Colors Acting Director Raymond Decker's stint as temporary head of the program recently was extended and could continue for some time given the government's focus on terrorism, the agency said

FDA Cosmetics & Colors Permanent Director Sought But Not Imminent

FDA Office of Cosmetics & Colors Acting Director Raymond Decker's stint as temporary head of the program recently was extended and could continue for some time given the government's focus on terrorism, the agency said

VCRP Reporting Incentives To Boost Industry Participation Considered By FDA

FDA is considering adding incentives to the recently restored Voluntary Cosmetics Reporting Program to help increase company participation, Office of Cosmetics & Colors Director John Bailey, PhD, said at the Cosmetic, Toiletry and Fragrance Association's science conference in Boston Nov. 8-10.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS006291

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel